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BACKGROUND: One of the proposed mechanisms of trastuzumab-induced regression of human epidermal growth factor receptor
2-positive (HER2þ) tumours includes facilitation of antibody-dependent cell-mediated cytotoxicity (ADCC). Granulocyte-
macrophage colony-stimulating factor (GM-CSF) mediates ADCC. We presented our pilot study of adding GM-CSF to trastuzumab
in patients with trastuzumab-resistant HER2þ metastatic breast cancer.
METHODS: Patients with HER2þ metastatic breast cancer that progressed after trastuzumab þ/  chemotherapy were continued on
trastuzumab 2mgkg
–1intravenous weekly and GM-CSF 250mgm
–2subcutaneous daily. Patients were assessed for response every
8 weeks. Treatment was continued until disease progression or intolerable toxicity.
RESULTS: Seventeen patients were evaluable (median age 48 years, range 27–75 years). The median number of metastatic sites was
2 (range 1–3); the most common site was the liver (n¼10). The median number of prior regimens for metastatic disease was
2 (range 1–5). No objective disease response was observed, but five patients (29%) had stable disease for a median duration of
15.8 (range 10–53.9) weeks. The most common adverse event was rash at the injection site. No grade 4 or irreversible adverse
event was seen.
CONCLUSION: The addition of GM-CSF to trastuzumab alone had a modest clinical benefit and acceptable safety profile in heavily
pretreated patients with trastuzumab-resistant HER2þ metastatic breast cancer.
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Metastatic breast cancer is generally considered incurable by
standard chemotherapy. Nevertheless, it is a chemosensitive
disease. Among patients treated with chemotherapy, median
survival is 24 months, and 2–5% patients have disease-free
survival longer than 5 years. Multiple prognostic and predictive
factors determine the course of the disease and the response to
systemic treatment. One of these factors is expression of the
human epidermal growth factor receptor 2 (HER2), which is
overexpressed in B20% of breast cancers (Slamon et al, 2001).
The HER2 oncogene is a member of the HER family of tyrosine
kinase receptors. Amplification of HER2 results in overexpression
of the HER2 receptor, which correlates with several negative
prognostic variables, including oestrogen receptor-negative status,
high S-phase fraction, positive nodal status, mutated p53, and high
nuclear grade (Sjo ¨gren et al, 1998). Overexpression of the HER2
receptor in turn results in relative resistance to endocrine therapy
(Atalay et al, 2003) and is correlated with an aggressive form
of breast cancer and significantly shorter disease-free and overall
survival (Press et al, 1993; Seshadri et al, 1993; Ravdin
and Chamness, 1995; Cobleigh et al, 1999; Slamon et al, 1987).
As overexpression of HER2 receptor is such an important
prognostic and predictive factor (Pietras et al, 1995), targeting
this receptor with tumour-specific passive and active immunothera-
peutic treatments is a rational strategy.
The humanised monoclonal antibody trastuzumab was devel-
oped as a therapy targeted against HER2 receptor. In patients with
HER2-positive (HER2þ) metastatic breast cancer, response rates
to trastuzumab monotherapy range from 12 to 34%, median
duration of response is 9 months (Cobleigh et al, 1999; Nahta et al,
2004). Concomitant trastuzumab and chemotherapy are synergis-
tic and have resulted in better response rates, time to disease
progression, and overall survival than chemotherapy alone or
trastuzumab monotherapy. Therefore, concomitant trastuzumab
and chemotherapy is considered a standard of care in HER2þ
metastatic breast cancer (Seidman et al, 2001; Slamon et al, 2001;
Esteva et al, 2002; Stein et al, 2004; Marty et al, 2005).
Although the mechanisms by which trastuzumab induces
regression of HER2þ tumours are not known definitively,
proposed mechanisms include potentiation of chemotherapy
(Pegram et al, 1999), inhibition of tumour cell proliferation
(Baselga et al, 1998; Sliwkowski et al, 1999), and facilitation of
immune function through antibody-dependent cell-mediated
cytotoxicity (ADCC) (Lewis et al, 1993; Sliwkowski et al, 1999;
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sRepka et al, 2003). Thus, ADCC appears to be one of the most
important immune effector functions. Cytokines such as granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) may
augment ADCC by direct activation of immune cells or by
enhancement of tumour-associated antigens on tumour cells
(Sondel and Hank, 2001).
We hypothesised that adding GM-CSF to trastuzumab would
overcome trastuzumab resistance via enhancing ADCC. We hereby
present the results of our pilot study assessing the feasibility, safety
profile, and efficacy of adding GM-CSF to trastuzumab in women
with trastuzumab-resistant metastatic breast cancer.
PATIENTS AND METHODS
Trial design
All patients provided written informed consent prior to participat-
ing in the pilot study, and the study was reviewed and approved
by the Institutional Review Board at The University of Texas MD
Anderson Cancer Center. Eligible patients were women with
metastatic breast cancer who had HER2-overexpressing disease
(HER2 3þ by immunohistochemical staining or amplification by
fluorescence in situ hybridisation) that was progressing after
treatment with at least one cycle of trastuzumab with or without
chemotherapy. Patients were required to have an Eastern
Cooperative Oncology Group performance status score of 0 or 1,
an adequate haematological profile, and adequate liver, kidney,
and heart function. Patients also were required to have measurable
metastatic disease. Patients with only bone disease, only leptome-
ningeal disease, or only malignant pleural effusion were not
eligible.
Treatment
Trastuzumab was intravenously given as follows: a 4mgkg
–1
loading dose followed by 2mgkg
–1 every week for 4 weeks (one
cycle). A loading dose was not necessary if patients received
trastuzumab within 2 weeks before the start of study treatment.
Subcutaneous GM-CSF was given at 250mgm
–2 daily until the
absolute neutrophil count was 410000mm
–3, then was given
every other day to maintain the absolute neutrophil count below
10000mm
–3. When GM-CSF and trastuzumab were given on the
same day, GM-CSF was given before trastuzumab infusion.
Patients underwent restaging every 8 weeks (two cycles).
Granulocyte-macrophage colony-stimulating factor and trastuzu-
mab were continued until disease progression or intolerable toxic
effects. The primary end points of the trial were tumour response
(including stable disease) and time to progression. Treatment-
related toxicity was assessed according to the National Cancer
Institute Common Toxicity Criteria version 2.0. Tumour response
was assessed according to the Response Evaluation Criteria in
Solid Tumours system.
Statistical consideration
A maximum of 18 patients will be entered in the study. A 15%
(three patients) improved tumour response (including stable
disease) rate in this patient population would provide an impetus
towards further investigation of this treatment, including measure-
ment of ADCC.
RESULTS
Eighteen patients with progressive HER2þ metastatic breast
cancer were eligible, and 17 were evaluable (median age 48 years,
range 27–75 years) (Table 1). One patient did not complete the
first cycle because of a protocol violation. Among the 17 evaluable
patients, 9 had hormone receptor-positive disease. The median
number of sites of metastasis was 2 (range 1–3). The most
common site of metastasis was the liver (n¼10). The median
number of trastuzumab-containing regimens for metastatic disease
was 2 (range 1–5). One patient developed rapidly progressive
disease 2 weeks after the start of study therapy and died soon after.
Sixteen patients received treatment for at least 8 weeks (two cycles)
until disease progression. No disease response was observed, but
five patients (29%) had stable disease more than 8 weeks. The
median duration was 15.8 weeks (range 10–53.9 weeks). Three of
the five patients had hormone receptor-negative disease and four
of them had visceral organ involvement. Thirteen patients had
grade 1 adverse events; six patients had grade 2 adverse events; and
two patients had grade 3 adverse events (fatigue, muscle aches, and
paraesthesia). The most common adverse events, in decreasing
order of frequency, were rash at the GM-CSF injection site,
skin rash, fatigue, and muscle aches (Table 2). No grade 4 or
irreversible adverse event was seen.
DISCUSSION
Several proposed mechanisms of trastuzumab resistance included
downregulation of HER2, upregulation of expression of PTEN gene
or insulin-like growth factor receptor I gene, and also expression
of a truncated form of HER2 receptor – p95HER2 (Lu et al, 2001;
Table 1 Patient characteristics
a
Number of patients
Total 18
Evaluable 17
Age in years, median (range) 48 (27–75)
Initial disease stage
I1
II 5
III 6
IV 5
Hormone receptor status
Positive 9
Negative 8
HER2 receptor positive 18
Neoadjuvant chemotherapy 6
Anthracycline-containing regimen only 4
Anthracycline- and taxane-containing regimen 2
Adjuvant chemotherapy 9
Anthracycline-containing regimen only 2
Anthracycline- and taxane-containing regimen 3
Taxane-containing regimen only 4
Adjuvant radiation therapy 5
Adjuvant hormone therapy 3
Number of systemic regimens after metastasis, median (range) 2 (2–8)
Number of trastuzumab-containing regimens after metastasis,
median (range)
2( 1 – 5 )
Number of sites of metastasis, median (range) 2 (1–3)
Sites of metastasis
Liver 10
Bone 8
Lymph nodes 6
Lung 5
Chest wall 2
Brain 1
Peritoneum 1
aValues are numbers of patients unless otherwise specified.
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sScaltriti et al, 2007). Our pilot study has demonstrated the
potential for therapeutic synergy when trastuzumab is combined
with GM-CSF in patients with trastuzumab-resistant HER2þ
metastatic breast cancer. The addition of GM-CSF to trastuzumab
alone provided clinical benefit in 29% of heavily pretreated
patients without causing any grade 4 adverse events.
We tested a different approach to overcoming tumour resistance
to trastuzumab: enhancing the effect of trastuzumab through
addition of cytokines. One of the antitumour effects of trastuzu-
mab is through the action of innate effector mechanisms, such as
ADCC (Drebin et al, 1988; Kim et al, 2002; Spiridon et al, 2002). As
a mediator of ADCC, trastuzumab is detected as an abnormality on
the HER2 receptor of tumour cells by natural killer (NK) cells,
which in turn secrete cytokines and subsequently lead to tumour
cell death (Lewis et al, 1993; Sliwkowski et al, 1999). The GM-CSF
is commonly used to augment immune response by increases
antigen presentation of monocytes and macrocytes, enhances
CD20 expression, stimulates the effector function of myeloid cells
(i.e., neutrophils, macrophages, NK cells, and dendritic cells), and
enhances cell-mediated immunity (Dranoff, 2004; Niitsu et al,
2004; Olivieri et al, 2005). The GM-CSF also mediates ADCC via
stimulation of macrophages (Kushner and Cheung, 1989; Erbe
et al, 1990; Liesveld et al, 1991; Tarr, 1996), and the ability of GM-
CSF to increase the production of granulocytes and mononuclear
cells, as well as to enhance their cytotoxic activities against tumour
cells, is well documented (Kushner and Cheung, 1989; Erbe et al,
1990; Liesveld et al, 1991; Ragnhammar et al, 1992; Tarr, 1996; Yu
et al, 1997). The GM-CSF also can affect the migration of
granulocytes (Gasson et al, 1984; Barker et al, 1991), resulting in
their increased accumulation at tumour sites (Tseng et al, 1999).
Currently, GM-CSF is most often used in cancer treatment as a
stimulant of leukocyte production to protect against infection
(Jones et al, 1996; Beveridge and Miller, 1998). However, as
GM-CSF can augment immune effector cell functions (Kushner
and Cheung, 1989; Erbe et al, 1990; Liesveld et al, 1991; Tarr, 1996),
it also may enhance the therapeutic effect of monoclonal
antibodies, such as trastuzumab.
Several experimental and clinical studies have demonstrated the
antineoplastic effects of GM-CSF alone or in combination with
cytokines and/or monoclonal antibodies (Ragnhammar, 1996). The
GM-CSF has been shown to enhance anti-GD2-mediated ADCC by
granulocytes in disease-free subjects and in patients with
neuroblastoma (Yu et al, 1997; Batova et al, 1999). A recent pilot
trial found that continuous, low-dose GM-CSF had substantial
activity (objective response rate 37%) in heavily pretreated
patients with either metastatic breast cancer or female genital
tract cancer (Kurbacher et al, 2005). Enhancement of ADCC of
human peripheral blood mononuclear cells by GM-CSF has been
described (Grabstein et al, 1986; Thomassen et al, 1989), and
GM-CSF in conjunction with monoclonal antibodies has been used
in clinical trials for the treatment of colorectal carcinoma
(Mellstedt et al, 1991; Ragnhammar et al, 1992) and neuroblastoma
(Yu et al, 1997). Trial results found that GM-CSF augmented ADCC
activity of mononuclear cells and granulocytes against both
colorectal cancer cells and neuroblastoma; therapeutic efficacy
was demonstrated in these trials (Mellstedt et al, 1991; Ragnham-
mar et al, 1992; Yu et al, 1997). In this study, we have initially
designed to continue the trial in a phase II setting including
measurement of the ADCC activities under the influence of
GM-CSF and trastuzumab. However, we were not able to accrue
patients further to the study due to other competing trials in our
institution.
Although targeted therapies, such as combinations of trastuzu-
mab and chemotherapy, have been widely investigated for the
treatment of metastatic breast cancer, the role of cytokines, such as
GM-CSF, as an immunological stimulant in combination with
monoclonal antibodies, has been less well examined. Our pilot
study has demonstrated the potential for therapeutic synergy
with the combination of GM-CSF and trastuzumab. Administra-
tion of GM-CSF is simple, safe, and feasible. Although no disease
response was seen in our pilot study, our finding that this simple
approach stabilised breast cancer is clinically significant in this
setting of metastatic disease. This trastuzumab plus GM-CSF
regimen needs further evaluation in combination with chemo-
therapy or other biological agents in the management of metastatic
breast cancer. Further, there is a need to determine whether ADCC
activities are measured.
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